Company: RCUS
Filing Date: 2025-10-28
Form Type: 10-Q
Source: 0001724521-25-000116
Chunk: 195

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-28
Form: 10-Q
Item: Part I, Item 1
Chunk 195
---
Item 1. Financial Statements

ARCUS BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In millions, except per share amounts)

(unaudited)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Revenues:License and development services revenue (Includes $20, $23, $192 and $179 from a related party)$20 $41 $192 $204 Other collaboration revenue (Includes $6, $7, $22 and $28 from a related party)6 7 22 28 Total revenues26 48 214 232  Operating expenses:Research and development (Includes $13, ($2), $19 and ($32) from a related party)141 123 402 347 General and administrative(Includes $3, $—, $5, and $— from a related party)27 30 84 92 Impairment of long-lived assets (see Note 12, Leases)— — — 20 Total operating expenses168 153 486 459  Loss from operations(142)(105)(272)(227) Non-operating income (expense):Interest and other income, net10 14 31 40 Interest expense(3)(1)(6)(2)Total non-operating income, net7 13 25 38  Loss before income taxes(135)(92)(247)(189) Income tax expense— — — —  Net loss$(135)$(92)$(247)$(189) Net loss per share:Basic and diluted$(1.27)$(1.00)$(2.39)$(2.11)Shares used to compute net loss per share:Basic and diluted106.5 91.4 103.7 89.6

See accompanying notes.

1

Table of Contents

ARCUS BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In millions)

(unaudited)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Net loss$(135)$(92)$(247)$(189)Other comprehensive income— 2 — 1 Comprehensive loss$(135)$(90)$(247)$(188)

See accompanying notes.

2

Table of Contents

ARCUS BIOSCIENCES, INC.

COND